Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
10 2021
Historique:
received: 24 08 2020
revised: 20 01 2021
accepted: 08 02 2021
pubmed: 27 2 2021
medline: 18 1 2022
entrez: 26 2 2021
Statut: ppublish

Résumé

End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test-retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen's d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log

Identifiants

pubmed: 33632769
pii: thoraxjnl-2020-216078
doi: 10.1136/thoraxjnl-2020-216078
pmc: PMC8461450
doi:

Substances chimiques

Peptide Fragments 0
Natriuretic Peptide, Brain 114471-18-0

Banques de données

ClinicalTrials.gov
['NCT03841344']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1032-1035

Subventions

Organisme : Wellcome Trust
ID : 205188/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008894/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205188/Z/16/Z
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/14/6/31350
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206632/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: FW, LK and AC are employees and shareholders of GlaxoSmithKline. AS is the principal investigator for the collaborative research grant from GlaxoSmithKline that funded this study. AS has undertaken consultancy work for General Electric and Actelion Pharmaceuticals. RC has received fees for lecturing and participation in advisory boards, from Actelion, Bayer, GSK and MSD. DGK has received fees for lecturing and participation in advisory boards, from Actelion, Bayer, GSK and MSD and fees for participation in Steering Committees for Actelion.

Références

Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Am J Respir Crit Care Med. 2017 Jul 15;196(2):228-239
pubmed: 28328237
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545975
Eur Respir J. 2012 Apr;39(4):945-55
pubmed: 21885399
Front Psychol. 2013 Nov 26;4:863
pubmed: 24324449
J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9
pubmed: 22133851
Am Heart J. 2004 Feb;147(2):218-23
pubmed: 14760316
Pulm Circ. 2019 Mar 18;:2045894019841990
pubmed: 30880632
Am J Respir Crit Care Med. 2020 Feb 15;201(4):458-468
pubmed: 31647310
JACC Cardiovasc Imaging. 2021 May;14(5):931-942
pubmed: 33008758

Auteurs

Andrew J Swift (AJ)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK a.j.swift@sheffield.ac.uk.

Frederick Wilson (F)

Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Marcella Cogliano (M)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Lindsay Kendall (L)

Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.

Faisal Alandejani (F)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Samer Alabed (S)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Paul Hughes (P)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Yousef Shahin (Y)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Laura Saunders (L)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Charlotte Oram (C)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

David Capener (D)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Alex Rothman (A)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Pankaj Garg (P)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Christopher Johns (C)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Matthew Austin (M)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Alistair Macdonald (A)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Jo Pickworth (J)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Peter Hickey (P)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Robin Condliffe (R)

Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.

Anthony Cahn (A)

Research and Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Department of Respiratory Medicine, Bedford Hospital, Bedford, UK.

Allan Lawrie (A)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

Jim M Wild (JM)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.

David G Kiely (DG)

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH